First-line endocrine therapy for hormone receptor positive and HER 2 negative metastatic breast cancer: A Bayesian network meta analysis

Researchers performed a meta-analysis to compare maintenance treatments for patients with HR+ HER2- metastatic breast cancer. They found that palbociclib plus an aromatase inhibitor showed significantly longer progression-free survival (PFS) up to the 36th month of follow‑up when compared with an aromatase inhibitor alone. They concluded that palbociclib plus an aromatase inhibitor appeared to be the optimal treatment for this disease type, considering its effects on overall survival, PFS, safety profile, rates of medical compliance, and route of administration.